Sickle Cell Disease Clinical Trials in Indianapolis, Indiana

4 studies are recruiting for sickle cell disease in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

   This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Innovative Hematology - Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana

   Locations

   9 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT07187973 on ClinicalTrials.gov

2. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

3. A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

   The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana

   Locations

   3 in total

   Run by

   Agios Pharmaceuticals, Inc.

   See if you can join NCT07656415 on ClinicalTrials.gov

4. The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

   This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study detai…

   Stage

   Phase 3

   Ages

   10 to 65

   Site

   Indiana University Health Riley Hospital for Children- Site Number : 8400056, Indianapolis, Indiana

   Locations

   53 in total

   Run by

   Sanofi

   See if you can join NCT06975865 on ClinicalTrials.gov